» Articles » PMID: 34120177

SCORE2 Risk Prediction Algorithms: New Models to Estimate 10-year Risk of Cardiovascular Disease in Europe

Overview
Journal Eur Heart J
Date 2021 Jun 13
PMID 34120177
Citations 352
Affiliations
Soon will be listed here.
Abstract

Aims: The aim of this study was to develop, validate, and illustrate an updated prediction model (SCORE2) to estimate 10-year fatal and non-fatal cardiovascular disease (CVD) risk in individuals without previous CVD or diabetes aged 40-69 years in Europe.

Methods And Results: We derived risk prediction models using individual-participant data from 45 cohorts in 13 countries (677 684 individuals, 30 121 CVD events). We used sex-specific and competing risk-adjusted models, including age, smoking status, systolic blood pressure, and total- and HDL-cholesterol. We defined four risk regions in Europe according to country-specific CVD mortality, recalibrating models to each region using expected incidences and risk factor distributions. Region-specific incidence was estimated using CVD mortality and incidence data on 10 776 466 individuals. For external validation, we analysed data from 25 additional cohorts in 15 European countries (1 133 181 individuals, 43 492 CVD events). After applying the derived risk prediction models to external validation cohorts, C-indices ranged from 0.67 (0.65-0.68) to 0.81 (0.76-0.86). Predicted CVD risk varied several-fold across European regions. For example, the estimated 10-year CVD risk for a 50-year-old smoker, with a systolic blood pressure of 140 mmHg, total cholesterol of 5.5 mmol/L, and HDL-cholesterol of 1.3 mmol/L, ranged from 5.9% for men in low-risk countries to 14.0% for men in very high-risk countries, and from 4.2% for women in low-risk countries to 13.7% for women in very high-risk countries.

Conclusion: SCORE2-a new algorithm derived, calibrated, and validated to predict 10-year risk of first-onset CVD in European populations-enhances the identification of individuals at higher risk of developing CVD across Europe.

Citing Articles

Cardiac damage after polytrauma: the role of systematic transthoracic echocardiography - a pilot study.

Sztulman L, Ritter A, de Rosa R, Pfeiffer V, Leppik L, Busse L World J Emerg Surg. 2025; 20(1):21.

PMID: 40069898 PMC: 11895250. DOI: 10.1186/s13017-025-00596-5.


Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study.

Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, Weber D Lipids Health Dis. 2025; 24(1):88.

PMID: 40057729 PMC: 11889781. DOI: 10.1186/s12944-025-02500-1.


A mobile health application that supports a patient centered approach to cardiovascular risk management.

Li B, Heydari K, Enichen E, Kvedar J NPJ Digit Med. 2025; 8(1):150.

PMID: 40057621 PMC: 11890555. DOI: 10.1038/s41746-025-01549-7.


Clinically Accessible Liver Fibrosis Association with CT Scan Coronary Artery Disease Beyond Other Validated Risk Predictors: The ICAP Experience.

Garcia Izquierdo B, Martinez-Urbistondo D, Guadalix S, Pastrana M, Bajo Buenestado A, Colina I J Clin Med. 2025; 14(4).

PMID: 40004749 PMC: 11856594. DOI: 10.3390/jcm14041218.


Exploring the link between self-rated poor oral health and cardiovascular risk: a cross-sectional study using SCORE2.

Nymberg P, Milos-Nymberg V, Grundberg A, Oscarson N, Stenman E, Sundquist K BMC Oral Health. 2025; 25(1):298.

PMID: 39994610 PMC: 11853182. DOI: 10.1186/s12903-025-05671-6.


References
1.
Leitsalu L, Haller T, Esko T, Tammesoo M, Alavere H, Snieder H . Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. Int J Epidemiol. 2014; 44(4):1137-47. DOI: 10.1093/ije/dyt268. View

2.
DAgostino Sr R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-53. DOI: 10.1161/CIRCULATIONAHA.107.699579. View

3.
. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021; 42(25):2455-2467. PMC: 8248997. DOI: 10.1093/eurheartj/ehab312. View

4.
Schmermund A, Mohlenkamp S, Stang A, Gronemeyer D, Seibel R, Hirche H . Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk.... Am Heart J. 2002; 144(2):212-8. DOI: 10.1067/mhj.2002.123579. View

5.
Jaspers N, Blaha M, Matsushita K, van der Schouw Y, Wareham N, Khaw K . Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Eur Heart J. 2019; 41(11):1190-1199. PMC: 7229871. DOI: 10.1093/eurheartj/ehz239. View